Headquartered in Weybridge, Surrey we employ more than 35 people including offices in Dubai and Melbourne, Australia.
We use trusted contract partners to manufacture the medicines, while we distribute the medicines in the UK and overseas directly and via partners.
We are committed to the highest quality standards in our business, and that includes operating within the Medicines and Healthcare products Regulatory Agency (MHRA) regulatory framework.
Our experience in creating unlicensed medicines has driven our belief that a number of these products could provide therapeutic benefit to a wider group of patients if they were licensed. For that reason we are taking key products through regulatory approval processes in major territories.
As well as creating our own medicines, we also in-license products from other companies.
Unlicensed 'Special' Products
Our heritage of developing tailor-made medications enables Veriton Pharma to provide a range of unlicensed therapy options for those patients whose clinical needs are not met by licensed medications.
News
- SAPHNA Annual Conference 2019: HEALTH FOR ALL CHILDREN
SAPHNA Annual Conference 2019: 18th June in Manchester We are delighted to be attending the upcoming SAPHNA Annual Conference; HEALTH FOR ALL CHILDREN – School and Public Health Nurses Turning the Tide…. Read More
- Young Epilepsy online guide for school
Veriton Pharma is pleased to announce the online publication of the charity Young Epilepsy’s online guide for schools. This comprehensive resource aimed at improving the management and support of children with epilepsy… Read More
- Young Epilepsy and Veriton Pharma Ltd announce key partnership agreement in support of the charity’s ‘Rules 4 Schools’ campaign
Young Epilepsy and Veriton Pharma Ltd (Veriton) have announced a key agreement, where the organisations will work in partnership to deliver the ‘Rules 4 Schools” element of the charity’s newly… Read More
- Epistatus® 10 Mg (In 1 Ml) Oromucosal Solution Midazolam Available on Nhs Prescription Is Approved For Use By Both the Scottish Medicines Consortium (Smc) and the All Wales Medicines Strategy Group (Awmsg)
Epistatus is licensed for use in the treatment of prolonged, acute convulsive seizures in children and adolescents aged 10 to less than 18 years, who have been diagnosed with epilepsy1. Epistatus… Read More